Global Overactive Bladder (OAB) Treatment Market - Analysis By Medication, By Therapy, By Region, By Country (2019 Edition): Opportunities and Forecast (2019-2024) – By Region (N. America, Europe, APAC, ROW), By Country (US, Canada, Mexico, France, German

Global Overactive Bladder (OAB) Treatment Market - Analysis By Medication, By Therapy, By Region, By Country (2019 Edition): Opportunities and Forecast (2019-2024) – By Region (N. America, Europe, APAC, ROW), By Country (US, Canada, Mexico, France, Germany, Italy, Spain, China, India, Japan)

Executive Summary

Global Overactive Bladder Treatment Market was valued at USD 4978.09 Million in the year 2018. New emerging technologies and drug development with expanding health expenditure and infrastructure, rising number of elderly people etc. is driving the Overactive Bladder Treatment market. Further, advent of combination therapy, rising drug approval will bolster the overactive bladder treatment market. In addition, the ongoing developments and advancements of treatments in pharmaceutical industry will create the demand for high-efficient Overactive Bladder Treatment that are likely to boost the growth of Overactive Bladder Treatment market across all over the globe.

By Medication, Oxybutynin has been estimated to propel the market growth globally mainly owing to its cost effectiveness, good efficiency and lower rate of adherence in OAB treatment. By Therapy, BOTOX Treatment will have high growth rate, due to the fact that BOTOX is more cost-effective, even when performed in the hospital under general anesthesia. However, it can also be performed under local anesthesia. Furthermore, Botox is one-step procedure and does not require the implantation of a foreign body. BOTOX Therapy is an acceptable treatment for physicians as well and requires fewer extra skills beyond those necessary for a cystoscopic. Botox is safe, with the only side effect being the temporary need to catheterize in 6% of cases and UTI in 18% of cases.

Based on Therapy, SNM Therapy is expected to propel and have higher growth rate owing to its significantly higher completely dry rates and higher zero pad usage, improvement in frequency/urgency, and causes no change in voiding efficiency. Further, SNM therapy is more holistic than BOTOX Therapy and is a restorative therapy and returns function back to the patient. SNM does carry more complications (about 20%), mostly comprising undesirable stimulation and pain at the implant site.

Scope of the Report

Global Overactive Bladder Treatment Market (Actual Period: 2014-2018, Forecast Period: 2019-2024)

  • Overactive Bladder Treatment Market – Size, Growth, Forecast, By Value
  • Analysis By Medication: Oxybutynin, Tolterodine, Trospium, Solifenacin, Mirabegron, Others
  • Analysis By Therapy: BOTOX, SNM Therapy, PTNS
Regional Analysis – North America, Asia Pacific, Europe and Rest of World (Actual Period: 2014-2018, Forecast Period: 2019-2024)
  • Overactive Bladder Treatment Market – Size, Growth, Forecast, By Value
  • Analysis By Medication: Oxybutynin, Tolterodine, Trospium, Solifenacin, Mirabegron, Others
  • Analysis By Therapy: BOTOX, SNM Therapy, PTNS
Country Analysis – USA, Canada, Mexico, India, China, Japan, Germany, France, Italy, Spain (Actual Period: 2014-2018, Forecast Period: 2019-2024)
  • Overactive Bladder Treatment Market – Size, Growth, Forecast, By Value
  • Analysis By Medication: Oxybutynin, Tolterodine, Trospium, Solifenacin, Mirabegron, Others
  • Analysis By Therapy: BOTOX, SNM Therapy, PTNS
Other Report Highlights
  • Pipeline Product Analysis
  • Market Attractiveness Charts
  • Competitive Landscape
  • Leading Companies
  • Market Dynamics – Drivers, Trends and Restraints
  • Market Trends
  • SWOT Analysis
  • Porter’s Five Forces Analysis
  • Company Analysis – Sanofi S.A., Macleod’s pharmaceuticals Ltd., Apotex, Axonics modulation technologies, Intas Pharmaceuticals, Teva Pharmaceuticals, Laborie, Pfizer Inc., Allergan, Astellas Pharma Inc.
Customization of the Report

The report could be customized according to the client’s specific research requirements. No additional cost will be required to pay for limited additional research.


1. Report scope & Methodology
1.1 Scope of the Report
1.2 Research Methodology
1.3 Executive Summary
2. Strategic Recommendations
2.1 Asia Pacific region to witness augmented growth in the forecast period.
2.2 Contribution in Research and Development activities to expand the overactive bladder treatment products.
3. Global Overactive Bladder Product Outlook
Table 1: Treatment for OAB ( Without identifiable underlying causes: Idiopathic OAB)
Table 2: Treatment for OAB ( With identifiable underlying causes)
4. Global Overactive Bladder Treatment Market: An Analysis
4.1 Market Size, By Value, Year 2014-2024
Table 3: Global Overactive Bladder Treatment Market Size, By Value, 2014-2024 (USD Million)
Table 4: Share of People Aged 65+, 2015 and 2050F (In %)
Table 5: Prevalence of Urinary Incontinence worldwide (2018)
Table 6: Global estimates of individual with UI Grouped by year and region (In Millions)
Table 7: Estimated Number of Male with UI by year (Million)
Table 8: Estimated Number of Female with UI by year (Million)
Table 9: Estimated worldwide number of individuals with OAB Syndrome by year , by sex (In Million)
Table 10: Estimated total population number with OAB Syndrome by year (In Million)
Table 11: Estimated numbers of individuals in major world regions Affected by OAB (In Millions)
Table 12: Projected Global population (In Billions)
Table 13: Projected Global population aged 60 years & above (In Billions)
Table 14: OAB Prevalence, 2016
Table 15: GDP Per Capita PPP, By Select Countries, 2022F (USD)
Table 16: Expected Global Medical Spending in 2020, By Region, (% of Total)
Table 17: Healthcare Expenditure (Share of GDP), By Select Country, 2013-2018 (In %)
Table 18: Global Expected Healthcare Industry Outlook
Table 19: Regional Expected Healthcare Industry Growth Rate By Year 2020
5. Global Overactive Bladder Treatment Segmentation By Medication(By Value)
5.1 Competitive Scenario of Global Overactive Bladder Treatment Market – By Medication
Table 20:Competitive Scenario of Global Overactive Bladder Treatment Market – By Medication
5.2 Oxybutynin – Market Size and Forecast (2019-2024)
Table 21: Global Overactive Bladder Treatment Market- By Oxybutynin, By Value (USD Million), 2014-2024
5.3 Tolterodine – Market Size and Forecast (2019-2024)
Table 22: Global Overactive Bladder Treatment Market- By Tolterodine, By Value (USD Million), 2014-2024
5.4 Tropism – Market Size and Forecast (2019-2024)
Table 23: Global Overactive Bladder Treatment Market- By Trospium, By Value (USD Million), 2014-2024
5.5 Solifenacin – Market Size and Forecast (2019-2024)
Table 24: Global Overactive Bladder Treatment Market- By Solifenacin, By Value (USD Million), 2014-2024
5.6 Mirabegron – Market Size and Forecast (2019-2024)
Table 25: Global Overactive Bladder Treatment Market- By Mirabegron, By Value (USD Million), 2014-2024
5.7 Others – Market Size and Forecast (2019-2024)
Table 26: Global Overactive Bladder Treatment Market- By Others, By Value (USD Million), 2014-2024
6. Global Overactive Bladder Treatment Market Segmentation By Therapy(By Value)
6.1 Competitive Scenario of Global Overactive bladder treatment: By Therapy
Table 27:Competitive Scenario of Global Overactive Bladder Treatment– By Therapy
6.2 BOTOX– Market Size and Forecast (2019-2024)
Table 28: Global Overactive Bladder Treatment Market- By BOTOX Therapy, By Value (USD Million), 2014-2024
6.3 SNM Therapy- Market Size and Forecast (2019-2024)
Table 29: Global Overactive Bladder Market- By SNM Therapy, By Value (USD Million), 2014-2024
6.4 PTNS Therapy-Market Size and Forecast (2019-2024)
Table 30: Global Overactive Bladder Treatment Market- By PTNS, By Value (USD Million), 2014-2024
7. Global Overactive Bladder Treatment Market: Regional Analysis
7.1 Competitive Scenario of Global Overactive Bladder Treatment: By Region
Table 31: Competitive Scenario of Global Overactive Bladder Treatment– By Region
8. North America Overactive Bladder Treatment Market: By Analysis
8.1 North America Overactive Bladder Treatment Market: Size and Forecast (2019-2024)
Table 32: North America overactive bladder treatment Market Size, By Value, 2014-2024 (USD Million)
Table 33: North America Healthcare Cost Per Capita, 2017 (USD)
Table 34: North America Population above 65 year, 2015, 2030F, & 2050F (In Millions)
Table 35: North America GDP, 2012-2018 (USD Trillion)
Table 36: North America GDP per capita, current prices, 2013-2023F (In USD)
8.2 Market Segmentation By Medication
Table 37: North America Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Table 38: North America Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
8.3 Market Segmentation By Therapy
Table 39: North America Overactive Bladder Treatment Market- By Therapy, By Value (USD Million), 2014-2024
8.4 North America Global Overactive Bladder Treatment Market: Country Analysis
8.5 Market Opportunity Chart of North America Overactive Bladder treatment Market - By Country, By Value (Year-2024)
Table 40: Market Opportunity Chart of Overactive Bladder Treatment Market - By Country, By Value (Year-2024)
8.6 Competitive Scenario of North America Overactive Bladder treatment : By Country
Table 41:Competitive Scenario of North America Overactive Bladder treatment market – By Country
8.7 United States Overactive Bladder Treatment Market: Size and Forecast (2019-2024)
Table 42: United States overactive bladder treatment Market Size, By Value, 2014-2024 (USD Million)
Table A: Unites States, Hospitals Related Statistics, In 2018
Table 43: Unites States, Chronic Diseases Outlook, 2018
Table 44: U.S., Population ages 65 and above, 2014-2018 (% of total)
Table 45: U.S., Population ages 65 and above, Forecast (In Millions)
Table 46: Medical and Healthcare Research & Development Spending, 2013-2018 (In USD Billion)
Table 47: U.S., Per Capita Expenditure on Healthcare, 2012-2018 (In USD)
8.8 United States Overactive Bladder Treatment Market Segmentation By Medication, By Therapy
Table 48: United States Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Table 49: United States Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Table 50: United States Overactive Bladder Treatment Market- By Therapy, By Value (USD Million), 2014-2024
8.9 Canada Overactive Bladder Treatment Market: Size and Forecast (2019-2024)
Table 51: Canada Overactive Bladder Treatment Market Size, By Value, 2014-2024 (USD Million)
Table 52: Canada, Population ages 65 and above, 2012-2018 (% of total)
Table 53: Canada, Population Ageing Key Facts
Table 54: Overweight and Obese Population in Canada, 2015-2017 (% of total)
Table 55: Canada, Population Projections (In Millions)
Table 56: Canada, Expenditure on Health as a share of GDP, 2012-2017 (In %)
Table 57: Canada, Per Capita Healthcare Expenditure, 2012-2017 (USD)
8.10 Canada Overactive Bladder Treatment Market Segmentation By Medication, By Therapy
Table 58: Canada Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Table 59: Canada Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Table 60: Canada Overactive Bladder Treatment Market- By Therapy, By Value (USD Million), 2014-2024
8.11 Mexico Overactive Bladder Treatment Market: Size and Forecast (2019-2024)
Table 61: Mexico Overactive Bladder treatment Market Size, By Value, 2014-2024 (USD Million)
8.12 Mexico Overactive Bladder Treatment Market Segmentation By Medication, By Therapy
Table 62: Mexico overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Table 63: Mexico Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Table 64: Mexico Overactive Bladder Treatment Market- By Therapy, By Value (USD Million), 2014-2024
9. Europe Overactive Bladder Treatment Market: Segmentation By Medication, By Therapy (2019-2024)
9.1 Europe Overactive Bladder Treatment Market: Size and Forecast (2019-2024)
Table 65: Europe overactive bladder treatment Market Size, By Value, 2014-2024 (USD Million)
Table 66: EU-5 Socio-Economical Statistics, 2018
Table 67: Europe Union, Proportion of population aged 65 and over, 2014-2018 (% of Total Population)
Table 68: Europe, Per Capita Health Expenditure, By Select Country, 2017 (USD)
Table 69: GDP (Current USD), Europe Region, By Select Country, 2014-2018 (In Trillion USD)
Table 70 : European Country Population Aged 65 and Above, 2012-2018 (% of Total)
Table 71: GDP, Europe Region, By Select Country, 2012-2018 (In Trillion USD)
9.2 Market Segmentation By Medication
Table 72: Europe Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Table 73: Europe Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
9.3 Market Segmentation By Therapy
Table 74: Europe Overactive Bladder Treatment Market- By Therapy, By Value (USD Million), 2014-2024
9.4 Europe Global Overactive Bladder Treatment Market: Country Analysis
9.5 Market Opportunity Chart of Europe Overactive Bladder treatment Market - By Country, By Value (Year-2024)
Table 75: Market Opportunity Chart of Overactive Bladder Treatment Market - By Country, By Value (Year-2024)
9.6 Competitive Scenario of Europe Overactive Bladder treatment : By Country
Table 76: Competitive Scenario of Europe Overactive Bladder Treatment market – By Country
9.7 France Overactive Bladder Treatment Market: Size and Forecast (2019-2024)
Table 77: France overactive bladder treatment Market Size, By Value, 2014-2024 (USD Million)
Table 78: France, Health Infrastructure, 2017
Table 79: France, Healthcare Infrastructure Related Statistics
Table 80: France, Spending on Healthcare, 2015 & 2040,(USD Per Person)
Table 81: France, Population Ages 65 and Above (% of total), 2013-2018
Table 82: France, Number of Hospital Beds, 2013-2017
9.8 France Overactive Bladder Treatment Market Segmentation By Medication, By Therapy
Table 83: France Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Table 84: France Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Table 85 : France Overactive Bladder Treatment Market- By Therapy, By Value (USD Million), 2014-2024
9.9 Germany Overactive Bladder Treatment Market: Size and Forecast (2019-2024)
Table 86: Germany overactive bladder treatment Market Size, By Value, 2014-2024 (USD Million)
Table 87: Germany, Hospitals Relates Statistics, 2017
Table 88: Germany, Cause of Deaths, Percentage Change, 2007-2017
Table 89: Germany, Government R&D Spending on Health Research and Industry, (Euro Million), 2017
Table 90: Germany, Spending on Healthcare, 2015 & 2040E, (USD Per Person)
Table 91: Germany, Healthcare Related Statistics, 2017
9.10 Germany Overactive Bladder Treatment Market Segmentation By Medication, By Therapy
Table 92: Germany Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Table 93: Germany Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Table 94: Germany Overactive Bladder Treatment Market- By Therapy, By Value (USD Million), 2014-2024
9.11 Italy Overactive Bladder Treatment Market: Size and Forecast (2019-2024)
Table 95: Italy overactive bladder treatment Market Size, By Value, 2014-2024 (USD Million)
Table 96: Italy, Spending on Healthcare, 2015 & 2040, (USD Per Person)
Table 97: Italy, Cause of Death, Percentage Change Between 2007-2017
Table 98: Italy, Health Expenditure, (% of GDP), 2014-2018 (USD)
Table 99: Italy, Population Ages 65 and Above (% of total), 2012-2018
9.12 Italy Overactive Bladder Treatment Market Segmentation By Medication, By Therapy
Table 100: Italy Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Table 101: Italy Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Table 102: Italy Overactive Bladder Treatment Market- By Therapy, By Value (USD Million), 2014-2024
9.13 Spain Overactive Bladder Treatment Market: Size and Forecast (2019-2024)
Table 103: Spain Overactive bladder treatment Market Size, By Value, 2014-2024 (USD Million)
9.14 Spain Overactive Bladder Treatment Market Segmentation By Medication, By Therapy
Table 104: Spain Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Table 105: Spain Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Table 106: Spain Overactive Bladder Treatment Market- By Therapy, By Value (USD Million), 2014-2024
10. APAC Overactive Bladder Treatment Market: Segmentation By Medication, By Therapy (2019-2024)
10.1 APAC Overactive Bladder Treatment Market: Size and Forecast (2019-2024)
Table 107: APAC overactive bladder treatment Market Size, By Value, 2014-2024 (USD Million)
Table B: Global Access to Healthcare Index, Ranking of Select Countries in Asia Pacific Region, 2017 (score out of 10)
Table 108: APAC, GDP, By Select Country, 2017 (In USD Trillion)
Table 109: World health expenditure as % of GDP
Table 110: Population ages 65 and above, APAC Region, By Select Countries, 2018 (% of total)
Table 111: Population ages 65 and above, APAC Region, By Select Countries, 2050 (% of total)
Table 112: Key Healthcare industry issues to be addressed
Table 113 : Obesity Rate, By Select Country, 2017 (In Percentage)
10.2 Market Segmentation By Medication
Table 114: APAC Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Table 115: APAC Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
10.3 Market Segmentation By Therapy
Table 116: APAC Overactive Bladder Treatment Market- By Therapy, By Value (USD Million), 2014-2024
10.4 APAC Global Overactive Bladder Treatment Market: Country Analysis
10.5 Market Opportunity Chart of APAC Overactive Bladder treatment Market - By Country, By Value (Year-2024)
Table 117: Market Opportunity Chart of Overactive Bladder Treatment Market - By Country, By Value (Year-2024)
10.6 Competitive Scenario of APAC Overactive Bladder treatment : By Country
Table 118:Competitive Scenario of APAC Overactive Bladder Treatment market – By Country
10.7 India Overactive Bladder Treatment Market: Size and Forecast (2019-2024)
Table 119: India overactive bladder treatment Market Size, By Value, 2014-2024 (USD Million)
Table 120: India, Physicians per 1000 Population, 2013-2017
Table 121: India, Hospital Beds per 1000 Population, 2013-2017
Table 122: India, Diseases Outlook
Table 123: India, Medical Industry Outlook
Table 124: India, Total Population, 2013-2023F (In Billion)
Table 125: India, Share of Urban Population, 2012-2018 (In %)
Table 126: India, Medical Tourism Market, 2016-2017, (USD Billion)
Table 127: India, Population ages 65 and above, 2013-2017
10.8 India Overactive Bladder Treatment Market Segmentation By Medication, By Therapy
Table 128: India Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Table 129: India Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Table 130: India Overactive Bladder Treatment Market- By Therapy, By Value (USD Million), 2014-2024
10.9 China Overactive Bladder Treatment Market: Size and Forecast (2019-2024)
Table 131: China overactive bladder treatment Market Size, By Value, 2014-2024 (USD Million)
Table 132: China, Healthcare Outlook
Table 133: China, Cause of Death, Percentage Change Between 2007-2017
Table 134: China, GDP Growth Per Year, 2015-2019 (In %)
Table 135: China, Share of Urban Population, 2012-2018 (In %)
Table 136: China, Total Population, 2013-2021F (In Billion)
10.10 China Overactive Bladder Treatment Market Segmentation By Medication, By Therapy
Table 137: China Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Table 138: China Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Table 139: China Overactive Bladder Treatment Market- By Therapy, By Value (USD Million), 2014-2024
10.11 Japan Overactive Bladder Treatment Market: Size and Forecast (2019-2024)
Table 140: Japan overactive bladder treatment Market Size, By Value, 2014-2024 (USD Million)
Table 141: Japan, GDP Growth Per Year, 2015-2019F (In %)
Table 142: Japan, Population ages 65 and above, 2012-2017 (% of total)
10.12 Japan Overactive Bladder Treatment Market Segmentation By Medication, By Therapy
Table 143: Japan Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Table 144: Japan Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Table 145: Japan Overactive Bladder Treatment Market- By Therapy, By Value (USD Million), 2014-2024
11. ROW Overactive Bladder Treatment Market: Segmentation By Medication, By Therapy (2019-2024)
11.1 ROW Overactive Bladder Treatment Market: Size and Forecast (2019-2024)
Table 146: ROW overactive bladder treatment Market Size, By Value, 2014-2024 (USD Million)
Table 147: Population ages 65 and above, By Select Country, 2018 (% of total11.2 Market Segmentation By Medication
Table C: Healthcare expenditure pattern in Middle East and North Africa, In 2017
Table D: Pharmaceutical expenditure in relation to healthcare expenditure in Middle East and North Africa, In 2017
Table 149: Latin America and Caribbean, Population ages 65 and above 2012-2018 (% of total)
Table 150: Latin America and Caribbean, Share of Urban Population in Total Population, 2012-2018
Table 151: Middle East and North Africa, Population ages 65 and above (% of total)
Table 152: Middle East and North Africa, GDP, 2012-2018 (In USD Trillion)
11.2 Market Segmentation By Medication
Table 153: ROW Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
Table 154: ROW Overactive Bladder Treatment Market- By Medication, By Value (USD Million), 2014-2024
11.3 Market Segmentation By Therapy
Table 155: ROW Overactive Bladder Treatment Market- By Therapy, By Value (USD Million), 2014-2024
12. Global Overactive Bladder Treatment Market Dynamics
12.1 Global Overactive Bladder Treatment Market Drivers
12.2 Global Overactive Bladder Treatment Market Restraints
12.3 Global Overactive Bladder Treatment Market Trends
13. Market Attractiveness and Strategic Analysis
13.1 Market Attractiveness
13.2 Market Attractiveness Chart of Global Overactive Bladder Treatment Market - By Medication (Year 2024)
Table 156: Market Attractiveness Chart of Global Overactive Bladder Treatment Market - By Medication (Year-2024)
13.3 Market Attractiveness Chart of Global Overactive Bladder Treatment Market - By Therapy (Year-2024)
Table 157: Market Attractiveness Chart of Global Overactive Bladder Treatment Market - By Therapy (Year-2024)
13.4 Market Attractiveness Chart of Global Overactive Bladder Treatment Market - By Region, By Value, (Year-2024)
Table 158: Market Attractiveness Chart of Global Overactive Bladder Treatment Market - By Region, By Value, (Year-2024)
13.5 Pipeline Products
13.6 New Technologies in Overactive Bladder Treatments
13.7 Key Pipeline Drugs in Overactive Bladder Treatment Market
Table E: Urovant pipeline products for OAB Treatment
13.8 Key new operative therapies in Overactive Bladder Treatment Market
Table F: Allergan pipeline products for OAB Treatment
Table G: Astellas pipeline products for OAB Treatment
14. Competitive Landscape
14.1 Market Share Analysis
14.2 SWOT Analysis
14.3 Porter’s Five Force Analysis
15. Company Profiles (Business Description, Financial Analysis, Business Strategy)
15.1 Astellas Pharma Inc.
Table 159: Astellas Pharma Inc. Sales (USD Billion), Year 2014-2018
Table 160: Astellas Pharma Inc. Net Profit/Loss (USD Billion), Year 2014-2018
Table 161: Astellas Pharma Inc. Sales by Geographical area (In Percentage), Year 2018
Table 162: Astellas Pharma Inc. Sales of main products (USD Billion), Year 2018
15.2 Allergan
Table 163: Allergan , Net Sales, 2014-2018 (USD Million)
Table 164: Allergan , By Segments, 2018 (%)
Table 165: Allergan , By Segment, 2017 (%)
15.3 Pfizer Inc.
Table 166: Pfizer Inc. Total Revenue (USD Billion), Year 2014-2018
Table 167: Pfizer Inc. Net Income (USD Million), Year 2014-2018
Table 168: Pfizer Inc. Revenue by National Market (In percentage)
Table 169: Pfizer Inc. Segment Revenue(USD Billion)
15.4 Laborie
15.5 Teva Pharmaceutical
Table 170: Teva Pharmaceuticals NetRevenue (USD Billion), Year 2014-2018
Table 171: Teva Pharmaceuticals Net Income (USD Billion), Year 2014-2018
Table 172: Teva Pharmaceuticals Revenue By geographical area (USD Million)
Table 173: Teva Pharmaceuticals Major product Revenue in North America (USD Million)
15.6 Intas Pharmaceutical Ltd.
Table 174: Intas Pharmaceuticals Ltd. Sales Revenue (USD Million), Year 2015-2019
Table 175: Intas Pharmaceuticals Ltd.Net Income (USD Million), Year 2015-2019
Table 176: Intas Pharmaceuticals Ltd. Revenue by National Market (In percentage)
15.7 Axonics Modulation Technologies, Inc.
Table 177: Axonics Net Revenue (USD Thousands), Year 2018-2017
15.8 Apotex
15.9 Macleods Pharmaceuticals Ltd.
15.10 Sanofi S.A.
Table 178: Sanofi S.A. Total Revenue (USD Billion), Year 2014-2018
Table 179: Sanofi S.A. Net Income (USD Million), Year 2014-2018
Table 180: Sanofi S.A, Revenue by Global Business Unit (USD Billion)
Table 181: Sanofi S.A. By operating segment (USD Billion)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook